Spherix Announces Termination of Arla License...(ial to study the use of Naturlose as a t...)

Date:6/23/2009

ial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the NASDAQ Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned n
'/>"/>

SOURCE Spherix Incorporated Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
2. Spherix Regains Full NASDAQ Compliance
3. Spherix to Exhibit at the BIO 2009 International Convention
4. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
5. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
6. Spherix Announces 2008 Financial Results
7. Spherix Reports 3rd Quarter Earnings
8. Spherix Transfers Stock Listing to Nasdaq Capital Market
9. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
10. Spherix Receives NASDAQ Bid Price Deficiency Letter
11. Spherix Reports 1st Quarter Earnings